Canaccord reiterates a Buy rating on PacBio (PACB) with a $3 price target following the company’s Q4 report. The firm says that although PacBio ...

SoftBank disclosed a 20.45M share position in PacBio (PACB) and 14.67M share position in Recursion Pharmaceuticals (RXRX) in a regulatory ...

We hoped industry layoffs would relent in 2024. That's not what happened. Overall, biopharma layoffs rose 3% last year compared to 2023, according to an analysis of yearly data. So, here we are ...